title: [A case of transverse colon cancer with multiple liver metastases and hepatic pedicle lymph node involvement showing pathological complete response by XELOX plus bevacizumab].
abstract: A 70-year-old woman was referred to our hospital because of abdominal pain. Abdominal computed tomography(CT)and colonoscopy revealed transverse colon cancer with multiple liver metastases, with involvement of the hepatic pedicle and superior mesenteric artery lymph nodes. The patient received eight courses of XELOX plus bevacizumab, and CT showed a decrease in the size of the liver metastases and hepatic pedicle lymphadenopathy. Right hemicolectomy, partial hepatectomy, and hepatic pedicle lymph node resection were performed. Histopathological examination of the resected tissue revealed no residual cancer cells, suggesting a pathological complete response. The patient remains well 7 months after operation, without any signs of recurrence. Surgical resection should be considered for patients with initially unresectable colon cancer with liver metastases and hepatic pedicle lymph nodes involvement if systemic chemotherapy is effective.
authors.affiliation: Dept. of Gastroenterological Surgery, Japanese Foundation For Cancer Research, Japan.
authors.forename: Toshiki
authors.initials: T
authors.lastname: Mukai
authors.forename: Takashi
authors.initials: T
authors.lastname: Akiyoshi
authors.forename: Rintaro
authors.initials: R
authors.lastname: Koga
authors.forename: Junichi
authors.initials: J
authors.lastname: Arita
authors.forename: Akio
authors.initials: A
authors.lastname: Saiura
authors.forename: Atsushi
authors.initials: A
authors.lastname: Ikeda
authors.forename: Yasutomo
authors.initials: Y
authors.lastname: Nagasue
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Oikawa
authors.forename: Keiko
authors.initials: K
authors.lastname: Yamakawa
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Konishi
authors.forename: Yoshiya
authors.initials: Y
authors.lastname: Fujimoto
authors.forename: Satoshi
authors.initials: S
authors.lastname: Nagayama
authors.forename: Yosuke
authors.initials: Y
authors.lastname: Fukunaga
authors.forename: Masashi
authors.initials: M
authors.lastname: Ueno
authors.forename: Mitsukuni
authors.initials: M
authors.lastname: Suenaga
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Mizunuma
authors.forename: Eiji
authors.initials: E
authors.lastname: Shinozaki
authors.forename: Chiriko
authors.initials: C
authors.lastname: Yamamoto
authors.forename: Toshiharu
authors.initials: T
authors.lastname: Yamaguchi
mesh_terms: D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D000069287:Capecitabine; D044684:Colon, Transverse / Q000473:pathology* / Q000601:surgery; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery; D008207:Lymphatic Metastasis; D010071:Oxaloacetates
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D010071:Oxaloacetates; D003841:Deoxycytidine; D000068258:Bevacizumab; D000069287:Capecitabine; D005472:Fluorouracil